International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting

Trial Profile

International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SENTINEL study
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2017 New trial record
    • 06 Dec 2016 Results assessing safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results assessing treatment outcomes presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top